rituximab,cyclophosphamide
biogen,roche
[]
maher et al. recital trial. rtx vs cyc in ctd-ild. equal efficacy in fvc and qol. rtx also improved mrss in ssc patients. less adverse events with rtx (445 vs 646). #acr22 abstr#0003 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC